CN113398248B - External medicine for improving skin flap blood circulation and preparation method thereof - Google Patents
External medicine for improving skin flap blood circulation and preparation method thereof Download PDFInfo
- Publication number
- CN113398248B CN113398248B CN202110853434.6A CN202110853434A CN113398248B CN 113398248 B CN113398248 B CN 113398248B CN 202110853434 A CN202110853434 A CN 202110853434A CN 113398248 B CN113398248 B CN 113398248B
- Authority
- CN
- China
- Prior art keywords
- skin
- expansion
- external medicine
- minoxidil
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an external medicine for improving skin flap blood circulation and a preparation method thereof, wherein the external medicine comprises 1000-5000IU/mL of basic fibroblast growth factor, 10-50 mg/mL of minoxidil and 100-300 mg/mL of urea. The invention develops a safe, convenient, high-efficiency and quick external medicine for preventing and treating related complications of skin distension and improving the blood circulation of skin distension. When the skin tissue of the patient has the symptoms of capillary hyperplasia, thinned skin, transparent expansion failure, and the like, the external medicine provided by the invention is used for improving the skin failure state during the expansion by adopting a local smearing mode on the surface of the expansion skin, promoting the regeneration of the expansion skin, and effectively preventing and treating the complications related to the expansion skin.
Description
Technical Field
The invention relates to the field of surgery-skin soft tissue plastic repair and reconstruction, in particular to the development of new drugs applied to skin soft tissue expander treatment, which improves the expansion efficiency and reduces the expansion related complications.
Background
Skin tissue defects are a common problem in plastic and repair reconstructive surgery, and soft tissue dilation techniques are ideal repair means because they can provide skin tissue of similar color, texture, etc. However, the complications of soft tissue dilation can reach 17.44%, which has a direct relationship with the limited ability of skin tissue regeneration. Clinically, the capillary hyperplasia of the dilated skin tissue, the thinning of the skin and translucency are early warning signs of poor dilation, and the progress of the signs can lead to severe complications such as skin ulcer, necrosis and the like. Pausing or terminating the expansion is a major measure to avoid complications when relevant pre-warning signs occur.
In order to improve the expansion efficiency and reduce the expansion related complications, means such as auxiliary drugs, stem cell injection and the like can be adopted in the expansion process. The currently known treatment means comprise botulinum toxin type A injection, CGF injection, gelatin sponge coating, stem cell injection, autologous fat transplantation and the treatment mode of spreading medicines on the surface of the skin to expand the skin, which has certain promotion effect, but has limited application value in practical clinical application, and the method is particularly as follows:
botulinum toxin injection a: intramuscular injection is needed for administration, pain is relatively high, and the patient acceptance is relatively poor; the trauma to the dilated area increases the risk of developing complications associated with dilating the skin; and the treatment effect is not exact.
Gelatin sponge coating: there are limitations to the use of gelatin sponges where coating is difficult, such as the face and head, or a large volume dilator.
CGF injection: blood collection is needed, and the blood quality of partial patients does not reach the standard; damage to the dilated area increases the risk of developing complications associated with dilating the skin.
Stem cell injection: the stem cells are required to be obtained through invasive operation or surgery, and the preparation process is time-consuming and labor-consuming; the method comprises the steps of carrying out a first treatment on the surface of the The ethical aspect is not clear at present; the trauma to the dilated area increases the risk of developing complications associated with dilating the skin.
Autologous fat transplantation: fat is required to be obtained through liposuction operation, and subcutaneous fat quantity of many patients is small, so that the transplanting requirement cannot be met.
Spreading medicine on the surface of skin, such as triamcinolone acetonide, sucralfate, papaverine, etc.: the side effects of the medicine are limited in clinical application
Disclosure of Invention
In order to solve the problems in the prior art, the invention develops the external medicine which is safe, convenient, efficient and quick, prevents and treats the skin related complications on the surface of the skin flap and improves the blood circulation of the skin on the surface of the skin flap. When the skin tissue on the surface of the skin flap of a patient has the symptoms of capillary hyperplasia, thinned skin, transparent expansion failure and the like, the external medicine provided by the invention is used for improving the skin failure state during expansion or after skin flap operation by adopting a local smearing mode on the surface of the skin, promoting the regeneration of the expanded skin and effectively preventing and treating the complications related to the expanded skin.
The invention adopts the technical scheme that:
an external medicine for improving the blood circulation of skin flap is prepared from basic fibroblast growth factor (1000-5000 IU/mL), minoxidil (10-50 mg/mL), urea (100-300 mg/mL), etc.
Preferably: the external medicine also comprises an oil phase auxiliary material.
Preferably: the oil phase auxiliary materials comprise one or more of stearic acid, span 60, stearyl alcohol, liquid paraffin, white vaseline and laurocapram.
Preferably: the external medicine also comprises an aqueous-oil phase auxiliary material.
Preferably: the water phase auxiliary material comprises one or more of polyacrylate 80, glycerol, sorbic acid, dimethyl sulfoxide and purified water.
A preparation method of an external medicine for improving skin flap blood circulation comprises the following steps:
(1) Dissolving minoxidil in dimethyl sulfoxide for use, and dissolving alkaline fibroblast growth factor in purified water for use;
(2) Heating and melting the oil phase auxiliary materials, and controlling the temperature at 75-80 ℃;
(3) Heating the water phase auxiliary materials except dimethyl sulfoxide to 75-80 ℃ and filtering;
(4) Adding the water phase auxiliary materials into the oil phase auxiliary materials while the water phase auxiliary materials are hot with stirring, and stirring until emulsification is complete;
(5) Adding minoxidil solution when the mixture is completely emulsified and the temperature is reduced to below 50 ℃, and continuing stirring;
(6) When the mixture is stirred to be solidified and the temperature is reduced to below 37 ℃, adding an alkaline fibroblast growth factor solution, and stirring until solidification;
(7) And (5) sterile packaging for standby.
Preferably: and (3) sealing and storing at 4 ℃ after packaging in the step (7).
The invention has the beneficial effects that:
compared with the prior art, the invention has the beneficial effects that:
the basic fibroblast growth factor (bFGF) has biological activity of promoting neovascular and mitosis proliferation of various cells, and the indication is that the healing of skin wound surfaces is promoted; minoxidil has strong arteriole dilating effect, and can influence skin fibroblast regeneration and promote skin growth by enhancing blood supply; the urea can increase the water content of the skin cuticle, soften the skin with excessive keratinization, has good moisturizing effect, and further enhances the permeation of other medicines.
The invention develops a safe, convenient, high-efficiency and quick external medicine for preventing and treating related complications of skin distension and improving the blood circulation of skin distension. When the skin tissue of the patient has the symptoms of capillary hyperplasia, thinned skin, transparent expansion failure, and the like, the external medicine provided by the invention is used for improving the skin failure state during the expansion by adopting a local smearing mode on the surface of the expansion skin, promoting the regeneration of the expansion skin, and effectively preventing and treating the complications related to the expansion skin.
The invention can effectively avoid the problems existing in the prior art and can effectively improve the effect of expanding the blood circulation of the skin flap; has no local skin irritation and systemic toxic side effects; the preparation is simple, has stable performance, is colorless and odorless, and is suitable for long-term external use; the patient has high acceptance of external preparation, and does not cause trauma to the expansion area, thereby reducing the occurrence risk of complications related to the expansion skin.
The invention can be used for treating clinically common complications related to skin expansion, expands the indications of the main component medicaments, and can create certain economic value. Meanwhile, the external medicine smearing mode is used, the complications related to the skin expansion can be effectively prevented and treated, the skin soft tissue expansion process is smoothly carried out, and sufficient skin tissues with similar skin colors, textures and the like are provided, so that the treatment of more congenital malformations and acquired injury patients is ensured, and the external medicine has certain social value.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is an effect diagram of a typical case 1;
fig. 2 is an effect diagram of exemplary case 2.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
An external medicine for improving skin flap blood circulation comprises basic fibroblast growth factor 1000-5000IU/mL, minoxidil 10-50 mg/mL, and urea 100-300 mg/mL. The external medicine of the invention can be prepared into different dosage forms, such as solution, powder, oil, ointment and the like according to the requirements and the pharmaceutical properties, and different auxiliary materials are selected according to different dosage forms. The addition amount of the auxiliary materials is added according to the properties of the auxiliary materials.
The following examples are based on the selection of the auxiliary materials, and the type and amount of the auxiliary materials may be adjusted, and will not be described in detail.
Example 1
An external medicine for improving skin flap blood circulation and a preparation method thereof,
(1) the following raw materials are accurately weighed:
50 ten thousand IU (about 5 g) of basic fibroblast growth factor freeze-dried powder, 5g of minoxidil freeze-dried powder, 20g of urea, 5mL of dimethyl sulfoxide, 3mL of laurocapram, 4.5g of stearic acid, 60.25 g of span, 4.5g of stearyl alcohol, 7g of liquid paraffin, 4.5g of white vaseline, 3.5g of polysorbate, 8g of glycerin, 0.2g of sorbic acid and a proper amount of purified water, and the total preparation of 100g.
(2) The minoxidil freeze-dried powder is dissolved in dimethyl sulfoxide for standby, and the alkaline fibroblast growth factor freeze-dried powder is dissolved in purified water for standby.
(3) Taking oil phase components of stearic acid, span 60, stearyl alcohol, liquid paraffin, white vaseline, laurocapram and ketone, heating and melting in water bath, and controlling the temperature at 75-80 ℃;
(4) heating aqueous phase components urea, polyacrylate 80, glycerol, sorbic acid and purified water to 75-80 ℃ and filtering;
(5) when the oil phase component and the water phase component are identical, adding the water phase component into the oil phase component with stirring, and continuously stirring in one direction until the emulsification is complete;
(6) adding minoxidil solution when the mixture is completely emulsified and the temperature is reduced to below 50 ℃, and continuing stirring;
(7) and (3) adding the alkaline fibroblast growth factor solution when the mixture is stirred to be solidified and the temperature is reduced to below 37 ℃, and stirring until solidification.
(8) Sterile packaging, and sealing and preserving at 4deg.C.
Example 2
Substantially the same as in example 1, except that: the following raw materials are accurately weighed:
10 ten thousand IU (about 1 g) of basic fibroblast growth factor freeze-dried powder, 2g of minoxidil freeze-dried powder, 27g of urea, 5mL of dimethyl sulfoxide, 3mL of laurocapram, 4.5g of stearic acid, 60.25 g of span, 4.5g of stearyl alcohol, 7g of liquid paraffin, 4.5g of white vaseline, 3.5g of polysorbate, 8g of glycerin, 0.2g of sorbic acid and a proper amount of purified water, and the total preparation of 100g.
Example 3
Substantially the same as in example 1, except that: the following raw materials are accurately weighed:
20 ten thousand IU (about 2 g) of basic fibroblast growth factor freeze-dried powder, 4g of minoxidil freeze-dried powder, 24g of urea, 5mL of dimethyl sulfoxide, 3mL of laurocapram, 4.5g of stearic acid, 60.25 g of span, 4.5g of stearyl alcohol, 7g of liquid paraffin, 4.5g of white vaseline, 3.5g of polysorbate, 8g of glycerin, 0.2g of sorbic acid and a proper amount of purified water, and the total preparation of 100g.
Example 4
Substantially the same as in example 1, except that: the following raw materials are accurately weighed:
40 ten thousand IU (about 4 g) of basic fibroblast growth factor freeze-dried powder, 6g of minoxidil freeze-dried powder, 20g of urea, 5mL of dimethyl sulfoxide, 3mL of laurocapram, 4.5g of stearic acid, 60.25 g of span, 4.5g of stearyl alcohol, 7g of liquid paraffin, 4.5g of white vaseline, 3.5g of polysorbate, 8g of glycerin, 0.2g of sorbic acid and a proper amount of purified water, and the total preparation of 100g.
Effect experiment
When the ointment prepared in the embodiment 1 is used and the skin tissue of a patient is expanded and has the symptoms of capillary hyperplasia, skin thinning, transparent expansion failure and other early warning signs, the topical application mode of the surface of the expanded skin is adopted, and the topical application of the ointment is carried out once in the morning and at the evening after the topical skin is cleaned. Pre-use symptoms: the dilated skin tissue has capillary hyperplasia, thinned skin and transparent appearance. Symptoms after use: the capillary hyperplasia of the dilated skin tissue is reduced, and the skin thickness is increased.
Typical case 1: as shown in fig. 1, in fig. 1: a is before treatment; b is 1 week of administration of the medicament of the invention. It can be seen that the skin hyperplasia and blood vessel expansion are reduced, the skin texture is improved, and the complications related to the expansion are improved.
Typical case 2: as shown in fig. 2, in fig. 2: a is before treatment; b is more than 1 month of using the medicine of the invention; c is more than 2 months of using the medicine. It can be seen that the skin hyperplasia and blood vessel expansion are reduced, the skin texture is improved, and the complications related to the expansion are improved.
Although embodiments of the present invention have been described above, it will be apparent to those skilled in the art that modifications and substitutions can be made without departing from the principles and spirit of the invention.
Claims (1)
1. A preparation method of an external medicine for improving skin flap blood circulation is characterized by comprising the following steps:
(1) the following raw materials are accurately weighed:
50 ten thousand IU of basic fibroblast growth factor freeze-dried powder, 5g of minoxidil freeze-dried powder, 20g of urea, 5mL of dimethyl sulfoxide, 3mL of laurocapram, 4.5g of stearic acid, 601.25g of span, 4.5g of stearyl alcohol, 7g of liquid paraffin, 4.5g of white vaseline, 3.5g of polysorbate, 8g of glycerol, 0.2g of sorbic acid and a proper amount of purified water, and preparing 100g in total;
(2) dissolving minoxidil lyophilized powder in dimethyl sulfoxide for use, and dissolving alkaline fibroblast growth factor lyophilized powder in purified water for use;
(3) heating and melting oil phase components of stearic acid, span 60, stearyl alcohol, liquid paraffin, white vaseline and laurocapram in water bath at 75-80deg.C;
(4) heating aqueous phase components including urea, polysorbate 80, glycerol, sorbic acid and purified water to 75-80deg.C, and filtering;
(5) when the oil phase component and the water phase component are identical, adding the water phase component into the oil phase component with stirring, and continuously stirring in one direction until the emulsification is complete;
(6) adding minoxidil solution when the mixture is completely emulsified and the temperature is reduced to below 50 ℃, and continuing stirring;
(7) when the mixture is stirred to be solidified and the temperature is reduced to below 37 ℃, adding an alkaline fibroblast growth factor solution, and stirring until solidification;
(8) sterile packaging, and sealing and preserving at 4deg.C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110853434.6A CN113398248B (en) | 2021-07-27 | 2021-07-27 | External medicine for improving skin flap blood circulation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110853434.6A CN113398248B (en) | 2021-07-27 | 2021-07-27 | External medicine for improving skin flap blood circulation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113398248A CN113398248A (en) | 2021-09-17 |
| CN113398248B true CN113398248B (en) | 2023-08-15 |
Family
ID=77687862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110853434.6A Active CN113398248B (en) | 2021-07-27 | 2021-07-27 | External medicine for improving skin flap blood circulation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113398248B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987000427A1 (en) * | 1985-07-18 | 1987-01-29 | Proctor Peter H | Topical composition and method for stimulating hair growth |
| EP0455422A2 (en) * | 1990-04-27 | 1991-11-06 | Merck & Co. Inc. | Method of treating or preventing baldness with compositions containing fibroblast growth factor |
| JP2002020242A (en) * | 2000-07-06 | 2002-01-23 | Lion Corp | Hair care preparation composition |
| JP2004161639A (en) * | 2002-11-11 | 2004-06-10 | Shiseido Co Ltd | Gray hair-preventing agent |
| CN104906102A (en) * | 2015-06-08 | 2015-09-16 | 南宁市第九人民医院 | Wet compressing preparation with functions of resisting skin flap infection and promoting healing and application thereof |
| US9173921B1 (en) * | 2015-03-23 | 2015-11-03 | Jaehyun Lim | Method of promoting hair growth by administration of bFGF |
| CN105412918A (en) * | 2015-11-18 | 2016-03-23 | 上海交通大学医学院附属第九人民医院 | Drug formula capable of dissolving cross-linked hyaluronic acid thrombosis |
| CN108883048A (en) * | 2016-02-04 | 2018-11-23 | 阿拉斯廷护肤公司 | For invasive and composition and method of the procedural skin care of Noninvasive |
| CN110279847A (en) * | 2019-05-17 | 2019-09-27 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Application of the FGF21 in the drug that preparation promotes ultra long random flap survival |
| CN111840287A (en) * | 2019-04-30 | 2020-10-30 | 健艾仕生物医药有限公司 | Application of compound in treating autoimmune skin disease caused by inflammation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090074729A2 (en) * | 1999-11-05 | 2009-03-19 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including fibroblasts |
| KR20080075494A (en) * | 2005-09-21 | 2008-08-18 | 다스크 테크날러지, 엘엘씨 | Methods and compositions for organ and tissue functionality |
| US7803357B2 (en) * | 2006-10-30 | 2010-09-28 | John V Cappello | Topical and transdermal treatments using urea formulation |
| CN103040860B (en) * | 2012-11-29 | 2018-08-14 | 刘学武 | A kind of method starting mammalian stem cell and chlorine dioxide are in the application for preparing drug for starting mammalian stem cell |
| US11628132B2 (en) * | 2018-10-05 | 2023-04-18 | Jupiter Wellness, Inc. | Minoxidil adjuvant therapies |
-
2021
- 2021-07-27 CN CN202110853434.6A patent/CN113398248B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987000427A1 (en) * | 1985-07-18 | 1987-01-29 | Proctor Peter H | Topical composition and method for stimulating hair growth |
| EP0455422A2 (en) * | 1990-04-27 | 1991-11-06 | Merck & Co. Inc. | Method of treating or preventing baldness with compositions containing fibroblast growth factor |
| JP2002020242A (en) * | 2000-07-06 | 2002-01-23 | Lion Corp | Hair care preparation composition |
| JP2004161639A (en) * | 2002-11-11 | 2004-06-10 | Shiseido Co Ltd | Gray hair-preventing agent |
| US9173921B1 (en) * | 2015-03-23 | 2015-11-03 | Jaehyun Lim | Method of promoting hair growth by administration of bFGF |
| CN107708721A (en) * | 2015-03-23 | 2018-02-16 | Hcell有限公司 | Promote natural on-off cycles of hair growth and the method and composition and manufacture method of pre-Anti-hair loss |
| CN104906102A (en) * | 2015-06-08 | 2015-09-16 | 南宁市第九人民医院 | Wet compressing preparation with functions of resisting skin flap infection and promoting healing and application thereof |
| CN105412918A (en) * | 2015-11-18 | 2016-03-23 | 上海交通大学医学院附属第九人民医院 | Drug formula capable of dissolving cross-linked hyaluronic acid thrombosis |
| CN108883048A (en) * | 2016-02-04 | 2018-11-23 | 阿拉斯廷护肤公司 | For invasive and composition and method of the procedural skin care of Noninvasive |
| CN111840287A (en) * | 2019-04-30 | 2020-10-30 | 健艾仕生物医药有限公司 | Application of compound in treating autoimmune skin disease caused by inflammation |
| CN110279847A (en) * | 2019-05-17 | 2019-09-27 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Application of the FGF21 in the drug that preparation promotes ultra long random flap survival |
Non-Patent Citations (1)
| Title |
|---|
| Reversible Alopecia with Localized Scalp Necrosis After Accidental Embolization of the Parietal Artery with Hyaluronic Acid;Qing Yang等;Aesth Plast Surg;第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113398248A (en) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOHNSON et al. | Cutaneous focal mucinosis: a clinicopathological and histochemical study | |
| JP4659980B2 (en) | Carbon dioxide-containing viscous composition | |
| CN108210887A (en) | A kind of Medical cold application and preparation method thereof | |
| JP2000319187A (en) | Carbon dioxide transcutaneous and transmucosal absorption composition | |
| KR20070089907A (en) | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | |
| CN101569640A (en) | Application of total asiaticoside to preparation of medicaments or cosmetics for preventing and curing striae gravidarum | |
| CN102670600A (en) | Medicinal product for inhibiting scar and promoting wound healing, and preparation method and application of medicinal product | |
| CN102670632A (en) | Medical application of pirfenidone in inhibition of skin scar formation | |
| CN103006491A (en) | Biological skin care product for removing growth lines and preparation method thereof | |
| CN106110389A (en) | A kind of moist dressing of skin wound and its preparation method and application | |
| AU1077895A (en) | Medicaments comprising relaxin and their use | |
| CN108175740A (en) | It is a kind of that there is effectively repair cream of prevention and pregrant abdominal stretch marks-removing effect and preparation method thereof | |
| JP2011088930A (en) | Carbon dioxide percutaneous and transmucosal absorption composition | |
| CN108498357A (en) | A kind of human-like collagen facial mask liquid and preparation method thereof | |
| CN105560078A (en) | Preparation method of facial mask containing ossein | |
| JP5643872B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| CN113398248B (en) | External medicine for improving skin flap blood circulation and preparation method thereof | |
| CN111358710A (en) | Moisture-preserving and soothing donkey-hide gelatin face cream and preparation method thereof | |
| CN103385838A (en) | Anti-freckle whitening emulsion | |
| JP5164438B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| CN106563121B (en) | BFGF bovine basic fibroblast growth factor gel is repairing the application in acne rosacea skin lesion | |
| EP1752132A2 (en) | Skin cosmetic compositions | |
| US20190321372A1 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
| CN108785128A (en) | A kind of Hydrolyzed Collagen liposome and preparation method thereof of polypropylene glycol modification | |
| CN108653304A (en) | A kind of pterostilbene nano-micelle external-use gel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |